

Portfolio example: Halozyme Therapeutics

Biotech company from the U.S.

Facts and Figures

Region: North America

Subsector: Biotechnology

Market capitalization: USD 5.7 bn*


Revenue 2021: USD 443 mn



Investment idea summary

- Platform technology for converting intravenous drugs into subcutaneous applications
- Halozyme Therapeutics has licensed its ENHANZE technology to leading pharmaceutical and biotechnology companies including Roche, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and Argenx.
- New Enzyme technology extends intellectual property to 2032 (EU) and 2034 (US)
- 4 new, innovative product candidates with potential launch in 2023 - 2025
- Recent Antares acquisition bring in an auto injector device platforms which could drive meaningful revenue opportunities

Brief overview of the rHuPH20 technology platform



ESG valuation of Sustainalytics

ESG Risk Rating

▼ 26.8

Negligible 0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+
--------------------	--------------	-------------------------	---------------	---------------

UN Global Compact

Compliant	Watchlist	Non-Compliant
------------------	-----------	---------------

Controversy scale

No evidence of relevant controversies

Controversial business areas

Animal testing

For illustrative purposes only. Holdings and allocations are subject to change. Any reference to a specific company or security does not constitute a recommendation to buy, sell, hold or directly invest in the company or securities.

Source: Halozyme Therapeutics, Bellevue Asset Management, Bloomberg, Sustainalytics, *as of May 6, 2022